Psyence Biomedical Ltd. – NASDAQ:PBM

Add to watchlist

$3.05

+0.79

+34.96%

Market closed

Open in 2 days

+627.39%

month

+627.39%

quarter

Market Cap	1.93M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Psyence Biomedical Ltd. (NASDAQ:PBM): Profit margin
2024	0	-51.15M

Psyence Biomedical Ltd. (NASDAQ:PBM): Debt to assets
2024	1132159	12.10M	1069.17%

Psyence Biomedical Ltd. (NASDAQ:PBM): Cash Flow
2023	-519.60K	0	1.17M
2024	-2.94M	-5.72K	2.35M

Psyence Biomedical Ltd. alternative data

Psyence Biomedical Ltd.
Employees

Psyence Biomedical Ltd. (NASDAQ:PBM): Employee count
Dec 2024	10

Psyence Biomedical Ltd.
Latest News

Friday, 27 December 2024
16:05	Psyence Biomed Announces Closing of $2.0 Million Private Placement	globenewswire.com
Monday, 23 December 2024
07:30	Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements	globenewswire.com
Tuesday, 17 December 2024
08:37	Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial	globenewswire.com
07:30	Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial	newsfilecorp.com
Sunday, 15 December 2024
09:30	CVS's Sell-Off May Be Overblown	seekingalpha.com
Thursday, 12 December 2024
14:06	CVS Health Hits 11-Year Low; PBM Legislation Could Slash Earnings By 50%, Says Analyst	investors.com
Tuesday, 10 December 2024
07:30	Psyence Biomed Executes Binding Agreements with Optimi Health Corp.	globenewswire.com
Friday, 6 December 2024
11:06	Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations	globenewswire.com
Tuesday, 3 December 2024
07:30	Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress	globenewswire.com
Tuesday, 19 November 2024
16:05	Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation	globenewswire.com
Tuesday, 12 November 2024
16:30	Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq	globenewswire.com
Thursday, 31 October 2024
09:30	Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs	globenewswire.com
Friday, 25 October 2024
09:42	Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care	globenewswire.com
Thursday, 24 October 2024
07:00	Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care	globenewswire.com
Thursday, 17 October 2024
07:00	Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development	globenewswire.com
Monday, 14 October 2024
10:43	Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical	globenewswire.com
Friday, 4 October 2024
16:05	Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant	globenewswire.com
Friday, 20 September 2024
11:20	Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs	globenewswire.com
Thursday, 19 September 2024
07:30	Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs	globenewswire.com
Wednesday, 18 September 2024
09:30	Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones	globenewswire.com
Monday, 16 September 2024
09:31	Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care	globenewswire.com
07:30	Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones	globenewswire.com
Friday, 13 September 2024
16:30	Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq	globenewswire.com
Monday, 9 September 2024
07:30	Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care	globenewswire.com
Friday, 6 September 2024
07:30	Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant	globenewswire.com
Friday, 30 August 2024
07:00	Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC	globenewswire.com
Tuesday, 27 August 2024
16:05	Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024	globenewswire.com
Tuesday, 13 August 2024
07:30	Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development	newsfilecorp.com
07:30	Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development	globenewswire.com
Wednesday, 31 July 2024
16:05	Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC	globenewswire.com

Frequently Asked Questions (FAQ)

What's the price of Psyence Biomedical Ltd. stock today?

One share of Psyence Biomedical Ltd. stock can currently be purchased for approximately $3.05.
When is Psyence Biomedical Ltd.'s next earnings date?

Unfortunately, Psyence Biomedical Ltd.'s (PBM) next earnings date is currently unknown.
Does Psyence Biomedical Ltd. pay dividends?

No, Psyence Biomedical Ltd. does not pay dividends.
How much money does Psyence Biomedical Ltd. make?

Psyence Biomedical Ltd. has a market capitalization of 1.93M.
What is Psyence Biomedical Ltd.'s stock symbol?

Psyence Biomedical Ltd. is traded on the NASDAQ under the ticker symbol "PBM".
What is Psyence Biomedical Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Psyence Biomedical Ltd.?

Shares of Psyence Biomedical Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Psyence Biomedical Ltd. have?

As Dec 2024, Psyence Biomedical Ltd. employs 10 workers.
When Psyence Biomedical Ltd. went public?

Psyence Biomedical Ltd. is publicly traded company for more then 3 years since IPO on 10 Dec 2021.
What is Psyence Biomedical Ltd.'s official website?

The official website for Psyence Biomedical Ltd. is psyencebiomed.com.
Where are Psyence Biomedical Ltd.'s headquarters?

Psyence Biomedical Ltd. is headquartered at 121 Richmond Street West, Toronto, ON.
How can i contact Psyence Biomedical Ltd.?

Psyence Biomedical Ltd.'s mailing address is 121 Richmond Street West, Toronto, ON and company can be reached via phone at +41 63467764.

Psyence Biomedical Ltd.

psyencebiomed.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

+41 63467764

121 Richmond Street West
Toronto, ON M5H2K1

CIK: 0001985062
ISIN: CA74449F1009
: